|
**Overview**: Chronic Lymphocytic Leukemia Mutations 1 Panel**Introduction**: The Chronic Lymphocytic Leukemia Mutations 1 Panel is a diagnostic tool designed to detect CLL mutations using whole blood or bone marrow samples. In India, CLL is the most common adult leukemia in Western populations but increasing in urban areas (incidence ~1â€"2 per 100,000), with mutations (TP53 7-15 percent, NOTCH1 10 percent, SF3B1 10-15 percent, MYD88, BIRC3, ATM, IGHV unmutated, ZAP70) guiding prognosis and targeted therapy (e.g., ibrutinib for TP53 mutated). High morbidity from under-testing in rural/low-SES patients, limited NGS access, delayed risk-adapted treatment leading to poor survival. Per hematology practices aligned with ICMR and Indian Society of Hematology guidelines, the test employs NGS for mutation analysis over 1-2 days with high sensitivity/specificity, valuable for prognostic stratification. This diagnostic falls under leukemia screening and targets CLL patients, addressing accurate detection to guide therapy. With elevated morbidity due to under-testing, the test supports public health efforts by enabling precise risk assessment and improving outcomes. Its blood/bone marrow-based approach ensures reliable detection.**Other Names**: CLL Mut Pnl 1.**FDA Status**: FDA approved, CLIA certified for molecular pathology/oncology/hematology, compliant with 2025 standards.**Historical Milestone**: NGS for CLL prognostic markers; in India, growing in hematology-oncology centers.**Purpose**: The test detects 8 parameters including TP53 to guide CLL mutation assessment, stratify prognosis, inform targeted therapy.**Test Parameters**: 1. TP53, 2. NOTCH1, 3. SF3B1, 4. MYD88, 5. BIRC3, 6. ATM, 7. IGHV, 8. ZAP70.**Pretest Condition**: No fasting required; patients should have confirmed CLL diagnosis.**Specimen**: 3 mL whole blood or bone marrow in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for NGS).**Medical History**: Patients should provide details on CLL stage, treatment, lymphocytosis, family cancer history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated high-risk mutations including progression, benefits of profiling, and minimal discomfort from blood/bone marrow draw.**Procedural Considerations**: The test involves sample processing using NGS by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low tumor burden can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: High-risk mutations indicate poor prognosis, necessitating specialist input. Low-risk may require follow-up.**Specialist Consultation**: Hematologists/oncologists should be consulted for management.**Additional Supporting Tests**: FISH for confirmation.**Test Limitations**: Covers selected genes; comprehensive approach required.**References**: Indian Journal of Hematology 2024, CLL Studies India 2023. |
